Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Sanofi draws up candidate shortlist for top job - source

Published 18/11/2014, 15:02
Sanofi draws up candidate shortlist for top job - source

By Noëlle Mennella

PARIS (Reuters) - Sanofi (PA:SASY) is drawing up a shortlist of candidates for the post of chief executive to replace Chris Viehbacher, ousted by the board last month, a source close to the French drugmaker told Reuters.

Sanofi's board met earlier on Tuesday and chose director Jean-Rene Fourtou to lead the appointments and governance committee that will be tasked with reviewing the shortlist and selecting the new CEO, said the source.

At the head of that committee, Fourtou will be replacing Weinberg, who will focus on his dual role of group chairman and interim CEO. But the committee will work in close cooperation with Weinberg, the source added, requesting anonymity.

Sanofi declined to comment. The group said in a statement earlier that it had named Bonnie Bassler, a molecular biology professor, as an independent board member.

The board did not disclose any names of candidates to the top executive job, nor did it give a timeline for the succession or for the next board meeting, the source said.

Olivier Bohuon, the French boss of artificial knee and hip maker Smith & Nephew (L:SN), AstraZeneca's (L:AZN) Pascal Soriot and former Wyeth boss Bernard Poussot have been suggested by industry observers as potential candidates.

Fourtou, who is honorary chairman of media groupVivendii (PA:VIV), is a graduate of the Ecole Polytechnique and has been on Sanofi's board for the past decade.

Fourtou, 75, is known for saving Vivendi from bankruptcy in 2002, ousting its CEO Jean-Bernard Levy in 2012 and piloting the past two years of the group's strategic overhaul away from telecoms and towards media.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Sanofi shares were up 1.1 percent by 1442 GMT.

The stock has fallen 9 percent since the last week of October, when uncertainties over Viehbacher's role surfaced in the French press and the drugmaker warned of an unexpected slowdown at its diabetes business, traditionally its cash cow.

Within days, Sanofi's board had sacked Viehbacher, its chief executive of six years, blaming his solitary management style and poor execution of the group's strategy. The sudden dismissal surprised investors who had hailed the CEO's efforts to strengthen the firm and make it more global.

(Writing by Natalie Huet; Editing by James Regan and Louise Heavens)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.